A
ABclonal Biotechnology
Antibody | Protein | Peptide | ELISA | Gene - ABclonal
About ABclonal Biotechnology
ABclonal is a biotechnology startup that operates in the life sciences market, providing research materials and services to scientists and researchers globally. The company specializes in the production and distribution of high-quality antibodies, peptides, and other biotechnology products. ABclonal's primary clients include universities, research institutions, and pharmaceutical companies.
The company's business model is centered on the production and sale of these research materials. They generate revenue by selling their products directly to researchers and institutions. Additionally, they offer a membership program where customers can earn discounts on their purchases.
ABclonal also engages in educational activities, hosting symposiums, and meetings to discuss recent advancements in the field of biotechnology. They also produce podcasts and articles to educate the public about the importance of vaccines and the role of women in STEM.
In the wake of the COVID-19 pandemic, ABclonal has highlighted the importance of mRNA-based vaccines, acknowledging the scientists and technicians who developed these life-saving tools. The company's commitment to education and advocacy for vaccination and gender equality in STEM fields sets it apart in the biotechnology industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Woburn, United States
- Employees
- 107
- Open positions
- None listed
- Dealroom signal
- 32.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 2 companies, latest Sep 2024
- Capital deployed
- $206K
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Dec 2021 | $165M | $660M | Sequoia · Luxin Venture Capital · CMB International Capital | ↗ |
| SERIES COther financing | Dec 2020 | $83M | $330M | HongShan · Sigma Square Capital · LYFE Capital · Lucion Venture Capital | — |
Growth signals
Latest recorded traffic for ABclonal Biotechnology is 61K monthly website visits, up 13% over the last three months. ABclonal Biotechnology's team declined 4.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Yurogen BiosystemsWorcester, United States
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ABclonal Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ABclonal Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.